The prevalence and diagnostic significance of aCCP antibodies and rheumatoid factor in rheumatoid arthritis patients;Porównanie czȩstości wystȩpowania i znaczenia diagnostycznego przeciwciał przeciwko cyklicznemu cytrulinowanemu peptydowi oraz czynnika reumatoidalnego w reumatoidalnym zapaleniu stawów

Reumatologia

Volumn 45, Issue 2, 2007, Pages 59-64

  Tuchocka Piotrowska, Aleksandra ^a,b   Białkowska Puszczewicz, Grazyna ^a   Puszczewicz, Mariusz ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Katedra i Klinika Reumatologiczno Rehabilitacyjna i Chorób Wewnetrznych AM im K Marcinkowskiego   (Poland)

Author keywords

Anti cyclic citrullinated peptide antibodies; Rheumatoid arthritis; Rheumatoid factor

Indexed keywords

EID: 34248379720     PISSN: 00346233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-324.
2. Carson DA. Reumatoid factor. In: Textbook of Rheumatology. Kelly WN, Harris ED Jr., Ruddy S, et al. (eds). Philadelphia 1981; 677-690.
3. Smolen JS. Autoantibodies in rheumatoid arthritis. In: Manual of biological markers of disease, van Venrooij WJ, Maini RN (eds). Kluwer Academic Publishers, Dordrecht, Boston, London 1996; C1: 1-18.
4. Biernacka E, Za̧bek J. Celowość oznaczania czynnika reumatoidalnego w zestawieniu z wartościa̧ wykrywania innych przeciwciał wystȩpuja̧cych w reumatoidalnym zapaleniu stawów. Reumatologia 2003; 41: 55-68.
5. Gioud-Paquet M, Auvinet M, Raffln T, et al. IgM rheumatoid factor (RF), IgA RF, IgE RF and IgG RF detected by ELISA in rheumatoid arthritis. Ann Rheum Dis 1987; 46: 65-71.
6. Jacoby RK, Jayson Ml, Cosh JA. Onset, early stages and prognosis of rheumatoid arthritis: a clinical study of 100 patients with 11 year follow-up. Br Med J1973; 2: 96-100.
7. Vossenaar ER, van Venrooij WJ, Pruijn GJM. Anti-CCP antibodies in (early) rheumatoid arthritis. In: From proteomics to molecular epidemiology: relevance of autoantibodies. Conrad K, Fritzler M, Meurer M, et al. (eds). Pabst Science Publishers, Lengerich 2002; 454-462.
8. Aletaha D, Eberl G, Nell VP, et al. Attitudes to early rheumatoid arthritis: changing patterns. Results of a survey. Ann Rheum Dis 2004; 63: 1269-1275.
9. Wolfe F. A comparison of IgM rheumatoid factor by nephelometry and latex methods: clinical and laboratory significance. Arthritis Care Res 1998; 11: 89-93.
10. Dubucquoi S, Solau-Gervais E, Lefranc D et al. Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis 2004; 63: 415-419.
11. von Essen R, Kurki P, Isomäki H, et al. Prospect for an additional laboratory criterion for rheumatoid arthritis. Scand J Rheumatol 1993; 22: 267-272.
12. Forslind K, Vincent C, Serre G, et al. Antifilaggrin autoantibodies in early rheumatoid arthritis. Scand J Rheumatol 2000; 29: 320-322.
13. Bizzaro N, Mazzanti G, Tonutti E, et al. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 2001; 47: 1089-1093.
14. Goldbach-Mansky R, Lee J, McCoy A, et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arhritis Res 2000; 2: 236-243.
15. Lindqvist E, Eberhardt K, Bendtzen K, et al. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005; 64: 196-201.
16. Rantapää-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48: 2741-2749.
17. Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43: 155-163.
18. van Gaalen FA, Visser H, Huizinga TW. A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis. Ann Rheum Dis 2005; 64: 1510-1512.
19. Bas S, Perneger TV, Seitz M, et al. Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology (Oxford) 2002; 41: 809-814.
20. Pinheiro GC, Scheinberg MA, Aparecida da Silva M, et al. Anti-cyclic citrullinated peptide antibodies in advanced rheumatoid arthritis. Ann Intern Med 2003; 139: 234-235.
21. Matsui T, Ozawa Y, Nakayama H, et al. Comparison of the clinical utilities of serological markers for the diagnosis of rheumatoid arthritis. Arthritis Rheum 2003; 48 (suppl.): 543.
22. Kroot EJ, de Jong BA, van Leeuwen MA, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000; 43: 1831-1835.
23. Visser H, le Cessie S, Vos K, et al. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002; 46: 357-365.
24. Meyer O, Labarre C, Dougados M, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003; 62: 120-126.
25. Suzuki K, Sawada T, Murakami A, et al. High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand J Rheumatol 2003; 32: 197-204.
26. Vallbracht I, Rieber J, Oppermann M, et al. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 2004; 63: 1079-1084.
27. Vossenaar ER, van Venrooij WJ. Anti-CCP antibodies, a highly specific marker for (early) rheumatoid arthritis. Clin App Immunol Rev 2004; 4: 239-262.
28. Agrawal S, Misra R, Aggarwal A. Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clin Rheumatol 2007; 26: 201-204.
29. Greiner A, Plischke H, Kellner H et al. Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis. Ann N Y Acad Sci 2005; 1050: 295-303.
30. De Rycke L, Peene I, Hoffman IEA et al. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 2004; 63: 1587-1593.